MySkin is a bio-research company focused on developing targeted pharmacological treatments for severe and intractable asthma using advanced drug discovery techniques. The company addresses the critical need for effective therapies in patients who do not respond to existing asthma medications.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe and intractable asthma patients often do not respond to existing asthma medications, creating a critical need for effective therapies. Current treatment options may fail to adequately control symptoms and prevent exacerbations in these patients.
Solution
TAK-Circulator is a bio-research company focused on developing targeted pharmacological treatments for severe and intractable asthma. The company utilizes advanced drug discovery techniques to identify and develop novel therapies. By focusing on patients who do not respond to existing medications, TAK-Circulator aims to address the unmet needs in this specific asthma population. The company's創薬事業 (drug development business) is dedicated to creating innovative solutions for those suffering from severe asthma.
Target Audience
The primary target audience includes individuals suffering from severe and intractable asthma who have not found relief from existing treatments, as well as the medical professionals who treat them.
Features
- Advanced drug discovery techniques for novel therapeutic development
- Focus on targeted pharmacological treatments
- Specialization in severe and intractable asthma